Edition –19th

Date – *July 2026*

Portfolio – *Growth*

Halozyme Therapeutics - [HALO]

HALO Stock Breakdown	
Dividend Yield*	N/A
Sector	Health Care
Industry	Biotechnology
EWM Initial Buy	6/4/2026
Closing Price on 6/4/2026	$71.75
EWM Price Target	$84

*As of 7/7/2026

HALO Synopsis

Economic Influence

Halozyme's revenue comes from royalties and licensing fees tied to its partners' drug sales, not consumer spending, which helps shield the company from the inflation and interest rate pressures.

Fundamental Factors

Halozyme has grown revenue every year for over a decade, with sales up nearly 40% this past year alone, while operating margins have climbed to 58%—a sign of a highly profitable, durable business

Technical Support

The daily chart of HALO shows a consolidation pattern that we believe will lead to a breakout to all time highs.

Industry Indicators

Major pharmaceutical companies are increasingly converting IV drug infusions into faster, at-home injections, and Halozyme has positioned itself as the go-to partner for this shift, most recently

See page 2 to read the FULL STORY

Did you know?

- ENHANZE-enabled therapies have been commercialized in more than 100 countries, with over one million patients treated using the platform.
- In recent years, Halozyme has invested in advanced auto-injector technologies and acquired additional drug-delivery platforms to broaden its capabilities.
- Halozyme reported record 2025 revenue of approximately $1.4 billion

Company Profile

- The company was founded in 1998.
- Based in San Diego, California.

STOCK STORIES	**Edition** –19th **Date** – *July 2026* **Portfolio** – *Growth*

Halozyme – Full Story

You may not know the name, but Halozyme is essentially the technology behind a range of revolutionary drug treatments. Its proprietary enzyme allows injectable cancer, autoimmune, and immunodeficiency drugs to be given as a quick at-home shot instead of an hours-long IV infusion at an infusion center.

The company has grown revenue every year for over a decade, with sales up 39% over the past year and operating margins climbing to 58%—a highly profitable and durable licensing model built around its patented rHuPH20 drug-delivery enzyme. Despite this growth and profitability, the stock trades at just 7.8x forward earnings, a steep discount to its peer average of 26.6x and well below its own 5-year average of 12.2x, suggesting the market hasn't fully priced in the durability of its earnings stream.

Turning to the technical picture, we believe investors are starting to buy into this story. The stock first showed up in our scanning process in early June, flagged by a favorable moving average setup and strong price action (green box). We entered the position shortly after, and the stock rallied from \$72 to \$82 without skipping a beat. Shares are now testing all-time highs, with resistance sitting at the dotted black line.

From here, we could see a Cup & Handle pattern take shape, with a pullback toward \$77 forming the "handle" before a potential move higher. This is a setup we like to see, as it could push our price target from \$84 up to \$95/share—a meaningful gain for the portfolio. We'll be watching closely for that pattern to confirm, with an eye toward adding to the position if it plays out.